期刊文献+

HPLC法测定阿法替尼片中主药和有关物质的含量 被引量:1

Quantitative determination of main component and related substances in afatinib tablets by HPLC
下载PDF
导出
摘要 目的:建立以高效液相色谱法测定阿法替尼片中主药和有关物质含量的方法,以控制该制剂的质量。方法:色谱柱为KromasilC18(250mm×4.6mm,5μm),流动相为乙酸铵水溶液(30mmol/L)-甲醇(25:75),流速为1.0ml/min,紫外检测波长为254nm,柱温30℃,进样量为20μl。结果:阿法替尼检测浓度的线性范围为60.13~600.45μg/ml(r=0.9996);平均回收率为99.41%,RSD为0.86%。结论:建立的检测方法简单,结果准确可靠,可用于阿法替尼片的质量控制。 Objective: To establish an HPLC method for the determination of the main component and related substances in afa- tinib tablets. Methods: The determination was performed on Kormasil CIS column (250 mm ×4.6 mm, 5 μm) with mobile phase composed of ammonium acetate solution( 30 retool/L) -methanol(25: 75) at a flow rate of 1.0 mL/min. The detection wavelength was set at 254 nm at 30 ℃. The injection size was at 20 μl. Results: The calibration curve of afatinib was linear in the range of 60.13 - 600.45μg/ml ( n = 5, r = 0. 999 6 ) , and the average recovery of afatinib was 99.41% ( RSD was 0.86% ). Conclusions : This method is rapid, accurate and reliable, and applicable for the quality control of afatinib tablets.
作者 李赫宇 赵玲
出处 《天津药学》 2016年第4期22-24,30,共4页 Tianjin Pharmacy
关键词 阿法替尼 含量测定 高效液相色谱法 有关物质 afatinib, content determination, HPLC, related substances
  • 相关文献

参考文献5

二级参考文献53

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CACancer J Clin, 2013,63(1 ) : 11-30.
  • 2Siegel R,Ma J,Zou Z, et al. Cancer statistics, 2014[ J]. CA Canc-er J Clin, 2014,64(1) : 9-29.
  • 3Keating GM. Afatinib : a review of its use in the treatment of ad-vanced non-small cell lung cancer[ J]. Drug,2014, 74(2) : 207-221.
  • 4Stopfer P, Marzin K, Narjes H,et al. Afatinib pharmacokinetics andmetabolism after oral administration to healthy male volunteers [ J ].Cancer Chemother Pharmacol,2012, 69(4) : 1051 -1061.
  • 5Wind S, Schmid M, Erhardt J, et al. Pharmacokinetics of afatinib, aselective irreversible ErbB family blocker, in patients with advancedsolid tumours [ J ]. Clin Pharmacokinet, 2013 , 52( 12) : 1101-1109.
  • 6Schnell D,Buschke S,Fuchs H,et al. Pharmacokinetics of afatinibin subjects with mild or moderate hepatic impairment [ J ]. CancerChemother Pharmacol, 2014,74(2) : 267-275.
  • 7Yang JC, Shih JY, Su WC, et ai. Afatinib for patients with lung ad-enocarcinoma and epidermal growth factor receptor mutations ( LUX-Lung 2) ; a phase 2 trial[ J]. Lancet Oncol, 2012 , 13(5):539-548.
  • 8Katakami N, Atagi S, Goto K,et al. LUX-Lung 4 : A Phase II Trialof Afatinib in Patients With Advanced Non-Small-Cell Lung CancerWho Progressed During Prior Treatment With Erlotinib, Gefitinib, or、Both[J]. J Clin Oncol, 2013, 31(27.) : 3335-3341.
  • 9Miller VA , Hirsh V,Cadrane J, et al. Afatinib versus placebo forpatients with advanced, metastatic non-small-cell lung cancer afterfailure of erlotinib,gefitinib, or both,and one or two lines of chemo-therapy (LUX-Lung 1) : a phase 2b/3 randomised trial [ J ] . LincetOncol, 2012,13(5) : 528-538.
  • 10Hirsh V, Cadranel J, Cong XJ,et al. Symptom and quality of lifebenefit of afatinib in advanced non-small-cell lung cancer patientspreviously treated with erlotinib or gefitinib results of a randomizedphase II b/M trial ( LUX-Lung 1 ) [ J]. J Thorac Oncol, 2013 , 8(2): 229-237.

共引文献374

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部